Research Data from University of California Update Understanding of Chronic Kidney Disease (Practical Considerations and Implementation of Sodium-Glucose Co-Transporter-2 Inhibitors in Chronic Kidney Disease: Who, When, and How? A Position...).

A recent study conducted by the University of California highlights the need to reduce kidney and cardiovascular risk in patients with chronic kidney disease (CKD). The study focuses on the use of sodium-glucose co-transporter-2 (SGLT2) inhibitors as a potential treatment option for CKD. The researchers recommend the use of SGLT2 inhibitors as co-first-line therapy with renin-angiotensin-aldosterone system (RAAS) inhibitors, and provide guidance on risk assessment and implementation of SGLT2 inhibitors in clinical practice. The study emphasizes the importance of education and awareness among healthcare providers and patients to dispel misconceptions about the safety of SGLT2 inhibitors. [Extracted from the article]